Assessing the variability and correlation between SUV and ADC parameters of head and neck cancers derived from simultaneous PET/MRI: A single-center study.

OBJECTIVE: Intratumoral heterogeneity is associated with poor outcomes in head and neck cancer (HNC) patients owing to chemoradiotherapy resistance. [18 F]-FDG positron emission tomography (PET) / Magnetic Resonance Imaging (MRI) provides spatial information about tumor mass, allowing intratumor heterogeneity assessment through histogram analysis. However, variability in quantitative PET/MRI parameter measurements could influence their reliability in assessing patient prognosis. Therefore, to use standardized uptake value (SUV) and apparent diffusion coefficient (ADC) parameters for assessing tumor response, this study aimed to measure SUV and ADC's variability and assess their relationship in HNC. METHODS: First, ADC variability was measured in an in-house diffusion phantom and in five healthy volunteers. The SUV variability was only measured with the NEMA phantom using a clinical imaging protocol. Furthermore, simultaneous PET/MRI data of 11 HNC patients were retrospectively collected from the National Cyclotron and PET center in Chulabhorn Hospital. Tumor contours were manually drawn from PET images by an experienced nuclear medicine radiologist before tumor volume segmentation. Next, SUV and ADC's histogram were used to extract statistic variables of ADC and SUV: mean, median, min, max, skewness, kurtosis, and 5th , 10th , 25th , 50th , 75th , 90th , and 95th percentiles. Finally, the correlation between the statistic variables of ADC and SUV, as well as Metabolic Tumor volume and Total Lesion Glycolysis parameters was assessed using Pearson's correlation. RESULTS: This pilot study showed that both parameters' maximum coefficient of variation was 13.9% and 9.8% in the phantom and in vivo, respectively. Furthermore, we found a strong and negative correlation between SUVmax and ADVmed (r = -0.75, P = 0.01). CONCLUSION: The SUV and ADC obtained by simultaneous PET/MRI can be potentially used as an imaging biomarker for assessing intratumoral heterogeneity in patients with HNC. The low variability and relationship between SUV and ADC could allow multimodal prediction of tumor response in future studies.

Diagnostic Reference Levels in PET Imaging at Chulabhorn Hospital, Thailand.

Diagnostic reference levels (DRLs) are an important tool for controlling radiation exposure and ensuring safety in medical applications. In Thailand, DRL data have been gathered and established for nuclear medicine diagnostics since 2021. However, there is a lack of information on PET imaging examinations. At the National Cyclotron and PET Scan Centre, Chulabhorn Hospital, radiopharmaceuticals are produced for medical imaging and research, and a wide range of PET/CT and PET/MRI examinations are performed. Our objective was to investigate the administered activity of radiopharmaceuticals in patients undergoing PET imaging, especially the existing data on DRLs in medical diagnostic imaging. Methods: This was a retrospective study on nuclear medicine patients at the National Cyclotron and PET Scan Centre in 2023. Statistical analysis, including the mean and the 75th percentile values, was conducted to determine DRLs according to the International Commission on Radiological Protection guidelines. Results: The center performed 8,711 PET/CT and PET/MRI studies with 13 protocols in 2023. The most commonly administered activity was 18F-FDG in oncology and neurology examinations, with DRLs of 186.11 and 136.16 MBq, respectively. These values were notably almost twice lower than several reports in other countries. Conclusion: There is a lack of comprehensive data on most DRLs for PET imaging at this center because of the nonwidespread use of several radiopharmaceuticals. However, the lower DRLs for 18F-FDG can highlight the need for ongoing investigation toward the establishment of local DRLs, as well as assurance on the safety and efficiency of radiation used in nuclear medicine.

Assessment of Area Radiation Dose for the National Cyclotron and PET Centre at Chulabhorn Hospital in Thailand.

The National Cyclotron and PET Centre at Chulabhorn Hospital offers nuclear medicine diagnostic services using state-of-the-art digital PET/CT and PET/MRI machines as well as other related devices. Additionally, the center plays a vital role by having a cyclotron to produce radiopharmaceuticals, which are used both in-house and in other hospitals throughout the country. Despite the center's strict adherence to international standards regarding the use of radioactive substances in patients, there remains a potential risk of radiation exposure for operators, workers, and the public due to radioactive contamination and emissions from unsealed sources. Hence, it is imperative to assess and continuously monitor radiation levels in the work area to ensure the utmost level of safety for personnel. Methods: This study used optically stimulated luminescence dosimeters to measure radiation levels in 17 areas, consisting of 9 controlled and 8 supervised areas. Over a 3-mo period, the average monthly radiation dose was recorded for each location. Results: The PET/CT room registered the highest radiation dose within the controlled area, with a monthly average of 1.81 ± 0.29 mSv, equivalent to an annual dose of 21.72 mSv. This higher dose can be attributed to the significant number of patients served in this room. In supervised areas, the nursing counter located between the examination room and the patient waiting area exhibited the highest radiation exposure. The average monthly dose measured at this location was 0.085 ± 0.019 mSv, resulting in an annual dose of 1.015 mSv. Conclusion: The evaluation of radiation dose in controlled and supervised areas indicated that the overall radiation level remains within the prescribed limits. However, the slight excess that was observed at the nursing counter indicates the need for improvement to ensure compliance with the as-low-as-reasonably-achievable principle. Continuous monitoring of radiation levels should be conducted annually to maintain safety standards and minimize the risk that workers and the general public will be exposed to radioactivity.

Diagnosis of Hepatocellular Carcinoma Using C11 Choline PET/CT: Comparison with F18 FDG, ContrastEnhanced MRI and MDCT.

PURPOSE: The aim of this study was to compare C11 choline and F18 FDG PET/CT, gadoxeticenhanced 3T MRI and contrastenhanced CT for diagnosis of hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Twelve chronic hepatitis B patients suspected of having HCC by abdominal ultrasonography received all diagnostic modalities performed within a oneweek timeslot. PET/CT results were analyzed visually by two independent nuclear medicine physicians and quantitatively by tumor to background ratio (T/B). Nine patients then had histopathological confirmation. RESULTS: Six patients had well differentiated HCC, while two and one patient(s) were noted with moderately and poorly differentiated HCC, respectively. All were detected by both CT and MRI with an average tumor size of 5.7±3.8 cm. Five patients had positive C11 choline and F18 FDG uptake. Of the remaining four patients, three with well differentiated HCC showed negative FFDG uptake (one of which showed negative results by both tracers) and one patient with moderately differentiated HCC demonstrated no C11 choline uptake despite intense F18 FDG avidity. The overall HCC detection rates with C11 choline and F18 FDG were 78% and 67%, respectively, while the sensitivity of F18 FDG for nonwell differentiated HCC was 100%, compared with 83% of C11 choline. The average T/B of C11 choline in welldifferentiated HCC patients was higher than in moderately and poorly differentiated cases (p=0.5) and vice versa with statistical significance for T/B of F18 FDG (p = 0.02). CONCLUSIONS: Our results suggested better detection rate in C11 choline for well differentiated HCC than F18 FDG PET. However, the overall detection rate of PET/CT with both tracers could not compare with contrastenhanced CT and MRI.

(11)C-Choline and FDG PET/CT Imaging of Primary Cholangiocarcinoma: A Comparative Analysis.

OBJECTIVES: This study aimed to compare the diagnostic values of (11)C-choline and (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with cholangiocarcinoma (CCA). METHODS: This prospective study was conducted on 10 patients (6 males and 4 females), aged 42-69 years, suspected of having CCA based on CT or magnetic resonance imaging (MRI) results. (11)C-choline and (18)F-FDG PET/CT studies were performed in all patients over 1 week. PET/CT results were visually analyzed by 2 independent nuclear medicine physicians and quantitatively by calculating the tumor-to-background ratio (T/B). RESULTS: No (11)C-choline PET/CT uptake was observed in primary extrahepatic or intrahepatic CCA cases. Intense (18)F-FDG avidity was detected in the tumors of 8 patients (%80). Two patients, who were (18)F-FDG negative, had primary extrahepatic CCA. Ki-67 measurements were positive in all patients (range; 14.2%-39.9%). The average T/B values of (11)C-choline and (18)F-FDG were 0.4±0.2 and 2.0±1.0 in all cases of primary CCA, respectively; these values were significantly lower for (11)C-choline (P<0.005). Both FDG and (11)C-choline PET/CT detected metastatic CCA foci in all 8 patients (two patients had no metastases). CONCLUSION: As the results suggested, primary CCA lesions showed a poor avidity for (11)C-choline, whereas (18)F-FDG PET/CT was of value for the detection of most primary CCA cases. In contrast to primary lesions, metastatic CCA lesions showed (11)C-choline avidity.